Finalized Series A funding, bringing total raised to date to $12MM to support proprietary platform that enables identification of disease-driving bacteria and development of therapies for inflammatory diseases. Appointed Paul Miller, PhD, as Chief Scientific Officer. Moved to specialized microbiology facility in New Haven’s Science Park.
Artizan Biosciences Announces Corporate Progress and Financing
June 10, 2019